Glucagon-like peptide-1 (GLP-1) receptor agonists have become pivotal in managing Type 2 Diabetes Mellitus (T2DM) and obesity. These medications, such as Ozempic (semaglutide) and Mounjaro (tirzepatide), mimic the incretin hormone GLP-1, providing various metabolic benefits. They enhance insulin secretion, suppress glucagon, delay gastric emptying, and promote satiety, which aids in weight loss.
GLP-1 receptor agonists are primarily indicated for glycemic control in T2DM, often alongside diet and exercise. Some, like semaglutide, are also approved for chronic weight management in adults with obesity. Additionally, certain agents have shown cardiovascular benefits, making them suitable for patients with T2DM and cardiovascular disease.
Common side effects include nausea, vomiting, and diarrhea, which usually decrease over time. Serious risks involve pancreatitis and contraindications in patients with specific thyroid conditions. While hypoglycemia risk is low when used alone, it can increase with insulin or sulfonylureas.
Recent studies suggest GLP-1 receptor agonists may offer cardiovascular and renal benefits. Trials like LEADER and SUSTAIN-6 have shown reductions in major cardiovascular events. Patients should be counseled on proper administration, lifestyle modifications, and monitoring to maximize therapeutic outcomes.
